{"id":"W2956888684","doi":"10.1016/s2352-3026(19)30109-7","title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":242,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"Merck Sharp and Dohme","keywords":"Medicine; Lenalidomide; Dexamethasone; Multiple myeloma; Clinical endpoint; Internal medicine; Interim analysis; Pembrolizumab; Adverse effect; Clinical trial; Oncology; Surgery; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001811387,0.00193315,0.002777337,0.0004476027,0.0005469251,0.001673333,0.001137484,0.001829851,0.01065879],"category_scores_gemma":[0.001557667,0.0008434572,0.002698153,0.0004803661,0.001321168,0.001909047,0.0006373589,0.0044491,0.00167082],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001206133,"about_ca_system_score_gemma":0.001301202,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00170332,"about_ca_topic_score_gemma":0.003899669,"domain_scores_codex":[0.9994295,0.0002635944,0.00003124253,0.0001159443,0.00004042575,0.0001192933],"domain_scores_gemma":[0.9993972,0.0001686221,0.0001260492,0.0000457142,0.00002798416,0.0002344947],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9785138,0.003699188,0.0002841095,0.0008297282,0.00106703,0.00004113526,0.00006197347,0.0003317141,0.001388811,0.000172394,0.001252519,0.01235762],"study_design_scores_gemma":[0.97641,0.0217055,0.0006805485,0.00003436961,0.0002711109,0.00002382299,0.00002044115,0.0001425948,0.00009190471,0.0001427692,0.0004657298,0.00001109523],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9724576,0.01119814,0.001042846,0.001874254,0.001397131,0.004800695,0.002471135,0.0002462283,0.00451201],"genre_scores_gemma":[0.9794394,0.004948271,0.001807554,0.002681914,0.0005549663,0.003948817,0.001790965,0.0000383951,0.004789639],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01065879,"threshold_uncertainty_score":0.03565723,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07617864432414798,"score_gpt":0.3729354676185405,"score_spread":0.2967568232943925,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}